Polina G. Ermishina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Polina G. Ermishina has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr S. Trukhmanov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
5 shared publications - Anna V. Paraskevova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
5 shared publications - Olga A. Storonova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
5 shared publications - Vladimir Trofimovich Ivashkin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
5 shared publications - Anastasia A. Makushina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - Victoria A. Mironova
Sechenov First Moscow State Medical University, Moscow, Russian Federation
3 shared publications
Latest Publications
- 12 November 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (5)
A New Diagnostic Index for Assessment of Laryngopharyngeal Symptoms in Patients With Gastroesophageal Reflux Disease
Aim: to determine the physical and chemical characteristics of laryngopharyngeal reflux (LPR) and the quantitative thresholds associated with laryngopharyngeal symptoms (LPS) in patients with gastroesophageal reflux disease (GERD), and to introduce a novel integral diagnostic laryngopharyngeal index (LP-index) for interpreting 24-hour hypopharyngeal-esophageal multichannel intraluminal impedance-pH (HEMII-pH) monitoring data. Materials and methods. This study evaluated 80 patients with established GERD who underwent outpatient examination at the Motility Lab of the V.Kh. Vasilenko Clinic of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology (Sechenov University) between September 2025 and March 2026. All patients presented with heartburn and regurgitation. Additionally, 40 patients reported laryngopharyngeal symptoms (LPS) — including throat pain, irritation, sour taste, cough and excess throat mucus—persisting for at least 8 weeks. At baseline, all participants completed the Reflux Symptom Index (RSI) questionnaire. Esophagogastroduodenoscopy (EGD) revealed non-erosive GERD in 73.3 % of patients and erosive esophagitis in 26.7 % of cases. Patients were divided into two equal groups based on the presence of LPS: Group 1 comprised patients with GERD without LPS ( n = 40), and Group 2 comprised patients with GERD and LPS ( n = 40). All participants underwent 24-hour HEMII-pH monitoring after manometric localization of the upper esophageal sphincter (UES), with the proximal pH sensor and impedance channel positioned 1 cm above the upper border of the UES. Results. Group 1 comprised patients with GERD without LPS ( n = 40, median age 45.1 [34.8; 53.3] years), and Group 2 comprised patients with GERD and LPS ( n = 40, median age 50.0 [37.0; 60.3] years; p = 0.108). The median Reflux Symptom Index score in Group 2 was 14 [3.5; 37.9]. High-resolution manometry ruled out diagnostically significant esophageal motility disorders. All participants underwent 24-hour HEMII-pH monitoring of the pharynx, esophagus, and stomach. The esophageal DeMeester score was 10.12 [3.51; 24.37] in Group 1 patients and 16.34 [8.55; 26.47] in Group 2 ( p = 0.42), allowing the conclusion that LPS development does not depend on the DeMeester score, and LPS may represent either extraesophageal manifestations of GERD or symptoms of laryngopharyngeal reflux disease. A total of 1,365 LPR episodes were detected in 80 patients: 71.9 % ( n = 981) were mixed and 28.1 % ( n = 384) were liquid. Gas reflux episodes were not recorded. Weakly acidic refluxes were recorded most frequently — 77.4 % ( n = 1057), weakly alkaline accounted for 14.2 % ( n = 194), and acidic episodes accounted for 8.4 % ( n = 114). In GERD patients without LPS, acidic LPR episodes were not recorded. Weakly acidic refluxes were recorded less frequently than in Group 2 (liquid, p < 0.01; mixed, p = 0.067). In GERD patients with LPS, unlike Group 1, liquid and mixed acidic LPR episodes were detected ( p < 0.001). The number of liquid weakly alkaline episodes showed no statistically significant difference between Groups 1 and 2 ( p = 0.905). Mixed weakly alkaline refluxes were registered more frequently in GERD patients without LPS compared to Group 2 ( p = 0.079). ROC analysis demonstrated the diagnostic value of the number of acidic liquid, acidic mixed, and non-acidic liquid LPR episodes for differentiating GERD patients with and without laryngopharyngeal symptoms (AUC = 0.650; p < 0.001). Meanwhile, non-acidic mixed LPR episodes did not demonstrate such diagnostic value (AUC = 0.518; p = 0.69). The percentage of pharyngeal bolus exposure time was significantly higher in GERD patients with LPS compared to GERD patients without LPS ( p < 0.001), confirming the effect of refluxate exposure time on LPS development. The LP-index was significantly higher in Group 2 (6.68 [4.01; 14.80] vs. 2.85 [1.80; 4.80]; p < 0.001), which can be regarded as evidence of the effect of LPR on the development of laryngopharyngeal symptoms. The area under the ROC curve for the LP-index was 0.912 (95% CI: 0.850–0.970), corresponding to excellent discriminatory power. The maximum Youden index value (0.725) was achieved at an LP-index threshold of 4.80 (sensitivity — 82.5 %, specificity — 90.0 %). A statistically significant association was identified between LPS development and a pathological LP-index (χ2 = 16.2; Fisher’s exact test p < 0.001). Identifying a pathological LP-index increases the odds of LPR-related laryngopharyngeal symptoms by 7-fold (OR = 7.00; 95% CI: 2.62–18.70; φ-coefficient = 0.451). Based on the data obtained, ROC analysis was performed to select a threshold number of LPR episodes contributing to the development of laryngopharyngeal symptoms in GERD patients. The area under the ROC curve for the number of LPR episodes was 0.680 (95% CI: 0.599–0.753; p < 0.001). The maximum Youden index value was achieved at a threshold of 3 LPR episodes. At this threshold, sensitivity was 76.25 % and specificity was 56.94 %. Conclusion. Based on 24-hour HEMII-pH monitoring data, ROC curve analysis demonstrated excellent discriminatory performance and high prognostic value of the novel integral laryngopharyngeal index (LP-index) in evaluating the association between laryngopharyngeal reflux episodes and the development of laryngopharyngeal symptoms in GERD patients. The threshold value for the LP-index was established at 4.80. Exceeding this cut-off level serves as objective evidence for the presence of LPR and its pathogenetic contribution to the development of LPS. Registration of 3 or more LPR episodes per 24 hours is associated with the possible development of laryngopharyngeal symptoms in patients with GERD. The numbers of acidic liquid, acidic mixed, and non-acidic liquid LPR episodes have the highest diagnostic value for differentiating GERD patients with and without laryngopharyngeal symptoms. The diagnostic and pathogenetic role of non-acidic mixed LPR episodes in the development of laryngopharyngeal symptoms requires further clinical investigation.
- 12 November 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (5)
A New Diagnostic Index for Assessment of Laryngopharyngeal Symptoms in Patients With Gastroesophageal Reflux Disease
Aim: to determine the physical and chemical characteristics of laryngopharyngeal reflux (LPR) and the quantitative thresholds associated with laryngopharyngeal symptoms (LPS) in patients with gastroesophageal reflux disease (GERD), and to introduce a novel integral diagnostic laryngopharyngeal index (LP-index) for interpreting 24-hour hypopharyngeal-esophageal multichannel intraluminal impedance-pH (HEMII-pH) monitoring data. Materials and methods. This study evaluated 80 patients with established GERD who underwent outpatient examination at the Motility Lab of the V.Kh. Vasilenko Clinic of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology (Sechenov University) between September 2025 and March 2026. All patients presented with heartburn and regurgitation. Additionally, 40 patients reported laryngopharyngeal symptoms (LPS) — including throat pain, irritation, sour taste, cough and excess throat mucus—persisting for at least 8 weeks. At baseline, all participants completed the Reflux Symptom Index (RSI) questionnaire. Esophagogastroduodenoscopy (EGD) revealed non-erosive GERD in 73.3 % of patients and erosive esophagitis in 26.7 % of cases. Patients were divided into two equal groups based on the presence of LPS: Group 1 comprised patients with GERD without LPS ( n = 40), and Group 2 comprised patients with GERD and LPS ( n = 40). All participants underwent 24-hour HEMII-pH monitoring after manometric localization of the upper esophageal sphincter (UES), with the proximal pH sensor and impedance channel positioned 1 cm above the upper border of the UES. Results. Group 1 comprised patients with GERD without LPS ( n = 40, median age 45.1 [34.8; 53.3] years), and Group 2 comprised patients with GERD and LPS ( n = 40, median age 50.0 [37.0; 60.3] years; p = 0.108). The median Reflux Symptom Index score in Group 2 was 14 [3.5; 37.9]. High-resolution manometry ruled out diagnostically significant esophageal motility disorders. All participants underwent 24-hour HEMII-pH monitoring of the pharynx, esophagus, and stomach. The esophageal DeMeester score was 10.12 [3.51; 24.37] in Group 1 patients and 16.34 [8.55; 26.47] in Group 2 ( p = 0.42), allowing the conclusion that LPS development does not depend on the DeMeester score, and LPS may represent either extraesophageal manifestations of GERD or symptoms of laryngopharyngeal reflux disease. A total of 1,365 LPR episodes were detected in 80 patients: 71.9 % ( n = 981) were mixed and 28.1 % ( n = 384) were liquid. Gas reflux episodes were not recorded. Weakly acidic refluxes were recorded most frequently — 77.4 % ( n = 1057), weakly alkaline accounted for 14.2 % ( n = 194), and acidic episodes accounted for 8.4 % ( n = 114). In GERD patients without LPS, acidic LPR episodes were not recorded. Weakly acidic refluxes were recorded less frequently than in Group 2 (liquid, p < 0.01; mixed, p = 0.067). In GERD patients with LPS, unlike Group 1, liquid and mixed acidic LPR episodes were detected ( p < 0.001). The number of liquid weakly alkaline episodes showed no statistically significant difference between Groups 1 and 2 ( p = 0.905). Mixed weakly alkaline refluxes were registered more frequently in GERD patients without LPS compared to Group 2 ( p = 0.079). ROC analysis demonstrated the diagnostic value of the number of acidic liquid, acidic mixed, and non-acidic liquid LPR episodes for differentiating GERD patients with and without laryngopharyngeal symptoms (AUC = 0.650; p < 0.001). Meanwhile, non-acidic mixed LPR episodes did not demonstrate such diagnostic value (AUC = 0.518; p = 0.69). The percentage of pharyngeal bolus exposure time was significantly higher in GERD patients with LPS compared to GERD patients without LPS ( p < 0.001), confirming the effect of refluxate exposure time on LPS development. The LP-index was significantly higher in Group 2 (6.68 [4.01; 14.80] vs. 2.85 [1.80; 4.80]; p < 0.001), which can be regarded as evidence of the effect of LPR on the development of laryngopharyngeal symptoms. The area under the ROC curve for the LP-index was 0.912 (95% CI: 0.850–0.970), corresponding to excellent discriminatory power. The maximum Youden index value (0.725) was achieved at an LP-index threshold of 4.80 (sensitivity — 82.5 %, specificity — 90.0 %). A statistically significant association was identified between LPS development and a pathological LP-index (χ2 = 16.2; Fisher’s exact test p < 0.001). Identifying a pathological LP-index increases the odds of LPR-related laryngopharyngeal symptoms by 7-fold (OR = 7.00; 95% CI: 2.62–18.70; φ-coefficient = 0.451). Based on the data obtained, ROC analysis was performed to select a threshold number of LPR episodes contributing to the development of laryngopharyngeal symptoms in GERD patients. The area under the ROC curve for the number of LPR episodes was 0.680 (95% CI: 0.599–0.753; p < 0.001). The maximum Youden index value was achieved at a threshold of 3 LPR episodes. At this threshold, sensitivity was 76.25 % and specificity was 56.94 %. Conclusion. Based on 24-hour HEMII-pH monitoring data, ROC curve analysis demonstrated excellent discriminatory performance and high prognostic value of the novel integral laryngopharyngeal index (LP-index) in evaluating the association between laryngopharyngeal reflux episodes and the development of laryngopharyngeal symptoms in GERD patients. The threshold value for the LP-index was established at 4.80. Exceeding this cut-off level serves as objective evidence for the presence of LPR and its pathogenetic contribution to the development of LPS. Registration of 3 or more LPR episodes per 24 hours is associated with the possible development of laryngopharyngeal symptoms in patients with GERD. The numbers of acidic liquid, acidic mixed, and non-acidic liquid LPR episodes have the highest diagnostic value for differentiating GERD patients with and without laryngopharyngeal symptoms. The diagnostic and pathogenetic role of non-acidic mixed LPR episodes in the development of laryngopharyngeal symptoms requires further clinical investigation.
- Open Access
- 5 September 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 35-44
Comparison of the Efficacy of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers in Achieving and Maintaining Endoscopic Remission in Erosive Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis
Aim: to compare the efficacy of proton pump inhibitors and potassium-competitive acid blockers (P-CABs) in achieving and maintaining endoscopic remission in erosive gastroesophageal reflux disease. Materials and methods. A systematic literature search using specified keywords was performed through June 17, 2025, in the MEDLINE/PubMed, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases. Results. A total of 2,758 patients from six studies were included in this systematic review and meta-analysis. The meta-analysis showed a trend in favor of P-CABs at week 4 of therapy, although the difference was not statistically significant: OR = 1.29; 95% CI: 0.93–1.80; p = 0.13. At week 8, P-CABs demonstrated a statistically significant advantage over proton pump inhibitors in achieving endoscopic remission: OR = 1.92; 95% CI: 1.39–2.64; p < 0.0001. P-CABs were also more effective than proton pump inhibitors in maintaining endoscopic remission: OR = 1.77; 95% CI: 1.42–2.21; p < 0.00001. Heterogeneity across these analyses was low ( I 2 = 0–4 %). Conclusion. P-CABs are an effective alternative to proton pump inhibitors for achieving and maintaining endoscopic remission in patients with erosive gastroesophageal reflux disease. Further prospective studies are needed to optimise treatment regimens, assess long-term safety, and compare the efficacy of different agents within the P-CAB class.
- 5 September 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 35-44
Open AccessComparison of the Efficacy of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers in Achieving and Maintaining Endoscopic Remission in Erosive Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis
Aim: to compare the efficacy of proton pump inhibitors and potassium-competitive acid blockers (P-CABs) in achieving and maintaining endoscopic remission in erosive gastroesophageal reflux disease. Materials and methods. A systematic literature search using specified keywords was performed through June 17, 2025, in the MEDLINE/PubMed, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases. Results. A total of 2,758 patients from six studies were included in this systematic review and meta-analysis. The meta-analysis showed a trend in favor of P-CABs at week 4 of therapy, although the difference was not statistically significant: OR = 1.29; 95% CI: 0.93–1.80; p = 0.13. At week 8, P-CABs demonstrated a statistically significant advantage over proton pump inhibitors in achieving endoscopic remission: OR = 1.92; 95% CI: 1.39–2.64; p < 0.0001. P-CABs were also more effective than proton pump inhibitors in maintaining endoscopic remission: OR = 1.77; 95% CI: 1.42–2.21; p < 0.00001. Heterogeneity across these analyses was low ( I 2 = 0–4 %). Conclusion. P-CABs are an effective alternative to proton pump inhibitors for achieving and maintaining endoscopic remission in patients with erosive gastroesophageal reflux disease. Further prospective studies are needed to optimise treatment regimens, assess long-term safety, and compare the efficacy of different agents within the P-CAB class.
- 1 January 2026
- Published by Dynasty Publishing House in Voprosy detskoj dietologii
- Vol. 24 (1)
Control of nocturnal gastroesophageal reflux in non-erosive reflux disease with proton pump inhibitor and rebamipide combination therapy: results of a prospective randomized study
Objective. To evaluate the efficacy of combination therapy with a proton pump inhibitor (PPI) and rebamipide compared to PPI monotherapy in controlling nocturnal gastroesophageal reflux (GER) in patients with non-erosive reflux disease (NERD), based on 24-hour pH-impedance monitoring in the nocturnal supine position. Patients and methods. This prospective randomized study included 39 patients with NERD. All patients were divided into two groups: the study group (n = 22) received omeprazole 20 mg/day and rebamipide 300 mg/day; the comparison group (n = 17) received omeprazole 20 mg/day. The duration of treatment was 4 weeks. Efficacy was assessed functionally using 24-hour pH-impedance monitoring before and after treatment, with analysis of nocturnal parameters in the supine position. Results. In the study group, the duration of the longest nocturnal GER episode decreased by 78% (p = 0.016), and there was a notable positive trend in the percentage of time with pH 5 minutes (p = 0.039) and a trend toward a difference in the change in the percentage of time with pH <4 (p = 0.051). Conclusion. Combination therapy with rebamipide and PPI demonstrated both statistically significant and clinically meaningful superiority over PPI monotherapy in controlling nocturnal GER in patients with NERD, as evidenced by a substantial reduction in acid exposure and the number of pathologically prolonged reflux episodes in the supine position. These findings support the inclusion of rebamipide in the treatment regimen for NERD to improve control of nocturnal symptoms. Key words: proton pump inhibitors, rebamipide, non-erosive reflux disease, epithelial protective therapy
- 1 January 2026
- Published by Dynasty Publishing House in Voprosy detskoj dietologii
- Vol. 24 (1)
Control of nocturnal gastroesophageal reflux in non-erosive reflux disease with proton pump inhibitor and rebamipide combination therapy: results of a prospective randomized study
Objective. To evaluate the efficacy of combination therapy with a proton pump inhibitor (PPI) and rebamipide compared to PPI monotherapy in controlling nocturnal gastroesophageal reflux (GER) in patients with non-erosive reflux disease (NERD), based on 24-hour pH-impedance monitoring in the nocturnal supine position. Patients and methods. This prospective randomized study included 39 patients with NERD. All patients were divided into two groups: the study group (n = 22) received omeprazole 20 mg/day and rebamipide 300 mg/day; the comparison group (n = 17) received omeprazole 20 mg/day. The duration of treatment was 4 weeks. Efficacy was assessed functionally using 24-hour pH-impedance monitoring before and after treatment, with analysis of nocturnal parameters in the supine position. Results. In the study group, the duration of the longest nocturnal GER episode decreased by 78% (p = 0.016), and there was a notable positive trend in the percentage of time with pH 5 minutes (p = 0.039) and a trend toward a difference in the change in the percentage of time with pH <4 (p = 0.051). Conclusion. Combination therapy with rebamipide and PPI demonstrated both statistically significant and clinically meaningful superiority over PPI monotherapy in controlling nocturnal GER in patients with NERD, as evidenced by a substantial reduction in acid exposure and the number of pathologically prolonged reflux episodes in the supine position. These findings support the inclusion of rebamipide in the treatment regimen for NERD to improve control of nocturnal symptoms. Key words: proton pump inhibitors, rebamipide, non-erosive reflux disease, epithelial protective therapy
- Open Access
- 25 June 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (2) , 69-82
The Effect of Combined Therapy with a Proton Pump Inhibitor and Rebamipide on the Clinical Course and Morphofunctional Changes of the Esophageal Mucosa in Patients with Non-Erosive Reflux Disease
Aim: to evaluate the effect of combined therapy with a proton pump inhibitor and rebamipide on clinical manifestations and morphofunctional changes in the esophageal mucosa in patients with non-erosive reflux disease.Materials and methods. The study included 39 patients with non-erosive reflux disease randomized into the main group (omeprazole 20 mg/day + rebamipide 300 mg/day) and the comparison group (omeprazole 20 mg/day). The duration of treatment was 4 weeks. Histological examination of esophageal mucosa biopsies (hematoxylin-eosin staining), morphometry of intercellular spaces, and immunohistochemical assessment of tight junction protein expression (claudin-1, -4, occludin) were performed. Symptoms were evaluated using the Likert scale.Results. The combined therapy group showed significant reductions in heartburn severity (p < 0.001) and belching (p = 0.004), with absent/mild symptoms in 63.7 and 72.4 % of patients, respectively. In the proton pump inhibitor monotherapy group, 53 % of patients retained moderate or severe heartburn. Morphologically, the combined group demonstrated reduced eosinophilic infiltration (p = 0.030). Occludin expression increased in both groups but reached statistical significance only in the monotherapy group (p = 0.046).Conclusion. The combined therapy with proton pump inhibitor and rebamipide improves symptoms and morphological outcomes in non-erosive reflux disease. Increased occludin expression suggests restored integrity of intercellular junctions. Further studies with larger cohorts and extended follow-up are needed to confirm these findings.
- 25 June 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (2) , 69-82
Open AccessThe Effect of Combined Therapy with a Proton Pump Inhibitor and Rebamipide on the Clinical Course and Morphofunctional Changes of the Esophageal Mucosa in Patients with Non-Erosive Reflux Disease
Aim: to evaluate the effect of combined therapy with a proton pump inhibitor and rebamipide on clinical manifestations and morphofunctional changes in the esophageal mucosa in patients with non-erosive reflux disease.Materials and methods. The study included 39 patients with non-erosive reflux disease randomized into the main group (omeprazole 20 mg/day + rebamipide 300 mg/day) and the comparison group (omeprazole 20 mg/day). The duration of treatment was 4 weeks. Histological examination of esophageal mucosa biopsies (hematoxylin-eosin staining), morphometry of intercellular spaces, and immunohistochemical assessment of tight junction protein expression (claudin-1, -4, occludin) were performed. Symptoms were evaluated using the Likert scale.Results. The combined therapy group showed significant reductions in heartburn severity (p < 0.001) and belching (p = 0.004), with absent/mild symptoms in 63.7 and 72.4 % of patients, respectively. In the proton pump inhibitor monotherapy group, 53 % of patients retained moderate or severe heartburn. Morphologically, the combined group demonstrated reduced eosinophilic infiltration (p = 0.030). Occludin expression increased in both groups but reached statistical significance only in the monotherapy group (p = 0.046).Conclusion. The combined therapy with proton pump inhibitor and rebamipide improves symptoms and morphological outcomes in non-erosive reflux disease. Increased occludin expression suggests restored integrity of intercellular junctions. Further studies with larger cohorts and extended follow-up are needed to confirm these findings.
- 1 January 2025
- Published by Dynasty Publishing House in Voprosy detskoj dietologii
- Vol. 23 (1)
Changes in esophageal functional state during combined acid-suppressive and epithelial protective therapy in patients with non-erosive reflux disease
Objective. To evaluate the effect of combination therapy with rebamipide and proton pump inhibitor (PPI) on the functional state of the esophagus in patients with non-erosive reflux disease (NERD). Patients and methods. The study included 60 patients, 39 of whom had a confirmed diagnosis of NERD and were randomized into two groups: the study group receiving combination therapy with rebamipide (300 mg/day) and omeprazole (20 mg/day), and the comparison group receiving omeprazole monotherapy (20 mg/day). The study also included 13 patients with functional heartburn and 8 patients with esophageal hypersensitivity, who were divided into two groups. The duration of treatment was four weeks. To assess the functional state of the esophagus and gastroesophageal junction, as well as the esophageal mucosal resistance, the values of esophageal 24-hour pH-impedance testing and high-resolution manometry before and after treatment were analyzed. Results. In patients with NERD receiving combination therapy, the percentage of time with pH <4 was statistically significantly lower in the follow-up examination after the end of treatment and withdrawal of medications compared to the period before treatment (p = 0.048). In patients receiving PPI monotherapy, no statistically significant changes in the percentage of time with pH <4 were found in the dynamics (p = 0.465). There were statistically significant differences in lower esophageal sphincter pressure between two groups after treatment (p = 0.017). However, analyzing this parameter within each group before and after treatment revealed no statistically significant changes in lower esophageal sphincter pressure. In patients with esophageal hypersensitivity and functional heartburn, changes in the values of esophageal 24-hour pH-impedance testing and highresolution manometry before and after treatment did not reach statistical significance in any of the examined groups. Conclusion. The use of combination therapy with PPI and rebamipide is a safe and effective method to achieve adequate acid suppression, including in the post-treatment period. This therapeutic approach may improve esophageal motility and the state of lower esophageal sphincter. Key words: proton pump inhibitors, non-erosive reflux disease, epithelial protective therapy
- 1 January 2025
- Published by Dynasty Publishing House in Voprosy detskoj dietologii
- Vol. 23 (1)
Changes in esophageal functional state during combined acid-suppressive and epithelial protective therapy in patients with non-erosive reflux disease
Objective. To evaluate the effect of combination therapy with rebamipide and proton pump inhibitor (PPI) on the functional state of the esophagus in patients with non-erosive reflux disease (NERD). Patients and methods. The study included 60 patients, 39 of whom had a confirmed diagnosis of NERD and were randomized into two groups: the study group receiving combination therapy with rebamipide (300 mg/day) and omeprazole (20 mg/day), and the comparison group receiving omeprazole monotherapy (20 mg/day). The study also included 13 patients with functional heartburn and 8 patients with esophageal hypersensitivity, who were divided into two groups. The duration of treatment was four weeks. To assess the functional state of the esophagus and gastroesophageal junction, as well as the esophageal mucosal resistance, the values of esophageal 24-hour pH-impedance testing and high-resolution manometry before and after treatment were analyzed. Results. In patients with NERD receiving combination therapy, the percentage of time with pH <4 was statistically significantly lower in the follow-up examination after the end of treatment and withdrawal of medications compared to the period before treatment (p = 0.048). In patients receiving PPI monotherapy, no statistically significant changes in the percentage of time with pH <4 were found in the dynamics (p = 0.465). There were statistically significant differences in lower esophageal sphincter pressure between two groups after treatment (p = 0.017). However, analyzing this parameter within each group before and after treatment revealed no statistically significant changes in lower esophageal sphincter pressure. In patients with esophageal hypersensitivity and functional heartburn, changes in the values of esophageal 24-hour pH-impedance testing and highresolution manometry before and after treatment did not reach statistical significance in any of the examined groups. Conclusion. The use of combination therapy with PPI and rebamipide is a safe and effective method to achieve adequate acid suppression, including in the post-treatment period. This therapeutic approach may improve esophageal motility and the state of lower esophageal sphincter. Key words: proton pump inhibitors, non-erosive reflux disease, epithelial protective therapy